Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1+, locally advanced/metastatic, squamous NSCLC

被引：0

作者：

Gao, Bo ^{[1
]}

Zhao, Jun ^{[2
]}

Huang, Dingzhi ^{[3
]}

Sun, Meili ^{[4
]}

Ma, Zhiyong ^{[5
,6
]}

Chu, Qian ^{[7
]}

Liu, Yunpeng ^{[8
]}

Wang, Zhehai ^{[9
]}

Li, Xin ^{[10
]}

Li, Hui ^{[11
]}

Zhang, Juan ^{[10
]}

Sun, Jingchao ^{[10
]}

Peng, Yanyan ^{[11
]}

Wu, Yi-Long ^{[12
,13
]}

机构：

[1] Blacktown Canc & Haematol Ctr, Blacktown, NSW, Australia

[2] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Thorac Oncol, Minist Educ Beijing, Beijing, Peoples R China

[3] Tianjin Canc Hosp, Tianjin, Peoples R China

[4] Jinan Cent Hosp, Jinan, Peoples R China

[5] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China

[6] Henan Canc Hosp, Zhengzhou, Peoples R China

[7] Tongji Hosp, Wuhan, Peoples R China

[8] China Med Univ, Hosp 1, Shenyang, Peoples R China

[9] Shandong Canc Hosp & Inst, Jinan, Peoples R China

[10] BeiGene Beijing Co Ltd, Beijing, Peoples R China

[11] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China

[12] Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China

[13] Guangdong Acad Med Sci, Guangzhou, Peoples R China

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 18卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

200

引用

页码：124 / 124

页数：1

共 50 条

[1] Safety and Efficacy of Sitravatinib plus Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC
Khan, N.
Newman, J.
Rahman, H.
Lee, C-S.
Kohn, N.
Seetharamu, N.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S373 - S374
[2] Safety and Efficacy of Sitravatinib plus Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Non-Squamous NSCLC
Zhao, J.
Wu, J.
Cui, J.
Wang, L.
Sun, M.
Gao, B.
Ma, Z.
Liu, Y.
Wang, Z.
Li, X.
Li, H.
Zhang, J.
Sun, J.
Fei, C.
Wu, Y. -L.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S374 - S374
[3] Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1+, locally advanced/metastatic, nonsquamous NSCLC
Gao, Bo
Zhao, Jun
Wu, Jingxun
Wang, Lifeng
Sun, Meili
Ma, Zhiyong
Liu, Yunpeng
Wang, Zhehai
Li, Xin
Li, Hui
Zhang, Juan
Sun, Jingchao
Peng, Yanyan
Wu, Yi-Long
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 123 - 124
[4] Sitravatinib plus tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic NSCLC
Gao, B.
Ma, Z.
Yu, X.
Huang, D.
Zhao, J.
Day, D.
Body, A. L.
Zhou, Q.
Chu, Q.
Pan, H.
Cui, J.
Chen, C.
Xiang, X.
Fei, C.
Yang, L.
Wu, Y-L.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S998 - S998
[5] Sitravatinib plus tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic non-small cell lung cancer (NSCLC)
Gao, B.
Ma, Z.
Yu, X.
Huang, D.
Zhao, J.
Day, D.
Body, A. L.
Zhou, Q.
Chu, Q.
Pan, H.
Cui, J.
Li, H.
Sun, J.
Zhang, J.
Fei, C.
Wu, Y-L.
[J]. ANNALS OF ONCOLOGY, 2022, 33 : S1 - S1
[6] Sitravatinib plus tislelizumab in patients with metastatic non-small cell lung cancer (NSCLC)
Zhou, Q.
Yu, X.
Gao, B.
Ma, Z.
Chu, Q.
Huang, D.
Zhao, J.
Day, D.
Body, A. L.
Pan, H.
Cui, J.
Li, H.
Sun, J.
Zhang, J.
Fei, C.
Wu, Y-L.
[J]. ANNALS OF ONCOLOGY, 2022, 33 : S1 - S2
[7] Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC)
Zhang, Feng
Bai, Yuxian
Fang, Weijia
Meng, Zhiqiang
Xiong, Jianping
Guo, Yabing
Zhang, Tao
Zhang, Jingdong
Ying, Jieer
Chen, Zhendong
Ren, Zhenggang
Chen, Yajin
Hao, Chunyi
Yang, Liu
Wang, Jun
Zhang, Juan
Yu, Fan
Fei, Cong
Wu, Xikun
Qin, Shukui
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[8] Sitravatinib plus tislelizumab in patients with metastatic non-small cell lung cancer (NSCLC)
Zhou, Q.
Yu, X.
Gao, B.
Ma, Z.
Chu, Q.
Huang, D.
Zhao, J.
Day, D.
Body, A. L.
Pan, H.
Cui, J.
Chen, C.
Xiang, X.
Fei, C.
Yang, L.
Wu, Y-L.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S996 - S997
[9] Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1-refractory/resistant unresectable or metastatic melanoma from a phase Ib study
Cui, C.
Pan, H.
Carlino, M. S.
Cui, J.
Wang, X.
Li, X.
Sun, J.
Yang, L.
Guo, J.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S1448 - S1448
[10] SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer
Zhao, Jun
Yu, Xinmin
Huang, Dingzhi
Ma, Zhiyong
Gao, Bo
Cui, Jiuwei
Chu, Qian
Zhou, Qing
Sun, Meili
Day, Daphne
Wu, Jingxun
Pan, Hongming
Wang, Lifeng
Voskoboynik, Mark
Wang, Zhehai
Liu, Yunpeng
Li, Hui
Zhang, Juan
Peng, Yanyan
Wu, Yi-Long
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (02)

← 1 2 3 4 5 →